Stock Research Report for Medicamen Biotech Ltd
Stock score of Medicamen Biotech Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Medicamen Biotech Ltd by subscribing to ETPrime.
Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you
*As per competitive benchmarking of annual price. T&C apply
Make Investment decisions
with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
Find new Trading ideas
with weekly updated scores and analysts forecasts on key data points
In-Depth analysis
of company and its peers through independent research, ratings, and market data
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company's focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. It also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.
What is Stock Reports Plus?
Stock Reports Plus is a comprehensive, company-specific analysis that includes Stock Ratings based on quantitative assessment of six components – earnings, fundamentals, relative valuation, risk, price momentum, and insider trading.
How often are these reports updated?
Reports are updated daily and scores for all stocks are updated once a week on Sundays. On rare occasions, the scores are recalculated during the week if a data issue or calculation error is discovered.
How are the scores calculated in this report?
Each score is evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Scores and recommendations are based solely upon market data and stati... Load More
Each score is evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Scores and recommendations are based solely upon market data and statistics on a scale of 1 to 10 (10 being most favorable). Load Less
How can I get these reports?
We are offering Stock Reports Plus worth Rs. 1499 annually as a complimentary offering to ETPrime Members. In order to access these reports, you are required to become a member of ETPrime.
Can I access these reports during the free trial period?
You can access these reports with the trial period offered on ETPrime membership plans.
For how long can I use Stock Reports Plus?
Stock Reports plus is a complimentary offer with ET Prime. You can access these reports as long as you're ETPrime member or April 2023, whichever is earlier.
Can I subscribe only to Stock Reports Plus?
No. Stock Reports Plus is a value addition offered to our ETPrime members on a complimentary basis.
Is there a limit to the number of reports I can access?
There is no limit on the quantity of reports you can access.